Mycenax Biotech Inc. (TPEX:4726)

Market Cap	9.37B
Revenue (ttm)	672.85M
Net Income (ttm)	-536.33M
Shares Out	206.61M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	305,249
Average Volume	491,060
Open	45.30
Previous Close	44.70
Day's Range	44.80 - 45.75
52-Week Range	37.20 - 65.20
Beta	1.07
RSI	61.71
Earnings Date	Mar 14, 2025

About Mycenax Biotech

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-dru...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2023, Mycenax Biotech's revenue was 652.62 million, a decrease of -10.88% compared to the previous year's 732.28 million. Losses were -682.85 million, 50.5% more than in 2022.